The one loop 3-point vertex functions of QCD in the maximal abelian gauge (MAG) are evaluated at the fully symmetric point at one loop. As a consequence the theory is renormalized in the various momentum (MOM) schemes which are defined by the trivalent vertices, as well as in the MS scheme. From these the two loop renormalization group functions in the MOM schemes are derived using the one loop conversion functions. In parallel we repeat the analysis for the Curci-Ferrari gauge which corresponds to the MAG in a specific limit. The relation between the Λ parameters in different schemes is also provided.LTH 985

We compute Green's functions with a bilinear quark operator inserted at non-zero momentum for a generalized momentum configuration to two loops. These are required to assist lattice gauge theory measurements of the same quantity in matching to the high energy behaviour. The flavour non-singlet operators considered are the scalar, vector and tensor currents as well as the second moment of the twist-2 Wilson operator used in deep inelastic scattering for the measurement of nucleon structure functions.Comment: 19 latex pages, 4 figures, anc directory contains electronic version of amplitude

Abstract. The vertex structure of QCD fixed in the maximal Abelian gauge (MAG) and CurciFerrari gauge is analysed at two loops at the fully symmetric point for the 3-point functions corresponding to the three momentum subtraction (MOM) renormalization schemes. Consequently the three loop renormalization group functions are determined for each of these three schemes in each gauge using properties of the renormalization group equation. LTH 10621 1 Introduction.

No abstract

Prof Zeuzem opened the symposium by acknowledging that there is a new era in hepatitis C virus (HCV) treatment, due to the availability of efficacious treatments that could eradicate the disease. Prof Pawlotsky outlined recent advances in the field of HCV and discussed the European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2015, which were released at the congress. These recommendations prioritise the available HCV treatments in Europe, from treatment-naïve to treatment-experienced patients and in the context of patients with various stages of HCV disease, and highlight the need to remain vigilant for possible drug–drug interactions (DDIs) between HCV direct-acting antiviral agent (DAA) treatments and regular pharmaceutical medications. Dr Bourlière then described the remaining challenges in HCV relating to treatment of certain patient populations, such as those with advanced disease and specific contraindications. Prof Foster presented the real-life challenges of treating a patient population that can have heterogeneous characteristics and presented the recent outcomes of nationally implemented programmes for HCV. Mr Charles Gore, a patient advocate, described the World Health Organization (WHO) policies in HCV and highlighted that government lobbying by physicians and patients was required to improve awareness and prioritise HCV treatment. Prof Afdhal then summarised the current impact of HCV on productiveness and patient outcomes, and spoke about the benefits of patient access programmes in expanding the pool of patients who can be treated along with the cost implications of the global eradication of HCV. Finally, Prof Zeuzem emphasised how HCV is currently perceived as a lower global priority compared with other viral diseases and that lobbying will be required to demonstrate how investments into the treatment of HCV patients would dramatically reduce the prevalence and long-term costs of the disease.